<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238055</url>
  </required_header>
  <id_info>
    <org_study_id>2008-09-031</org_study_id>
    <nct_id>NCT01238055</nct_id>
  </id_info>
  <brief_title>Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the
      treatment of advanced gastric cancer patients who had prior chemotherapy with
      fluoropyrimidine and platinum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II trial of Sunitinib and Docetaxel in advanced gastric cancer
      patients who had prior chemotherapy with Fluoropyrimidine and Platinum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progression</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel and Sunitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + Sunitinib</intervention_name>
    <description>Docetaxel 60 mg/m2 iv, every 3 weeks
Sunitinib 37.5 mg qd daily, every 3 weeks</description>
    <arm_group_label>Docetaxel + Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel only</intervention_name>
    <description>Docetaxel 60 mg/m2 iv</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or
             gastroesophageal junction adenoca (i.e. an adenocarcinoma with &gt; 50% extension in the
             stomach)

          2. patients must present with stage IV disease not amenable to surgery, radiation or
             combined modality therapy with curative intent. Patients previously undergoing local
             treatment (surgery and/or radiation) must have subsequently progressed or recurred

          3. prior chemotherapy wit fluoropyrimidine and platinum

          4. measurable or evaluable disease according to RECIST

          5. age, 18 years or older

          6. ECOG performance status 0 - 2

          7. adequate organ function as defined by the following criteria absolute neutrophil count
             (ANC) ≥ 1,500/ul platelets ≥ 100,000/ul AST/ALT ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver
             involvement Total serum bilirubin ≤ 2.0 mg/dL

          8. life expectancy of ≥ 3 months

          9. signed written informed consent

        Exclusion Criteria:

          1. more than one prior chemotherapy for metastatic disease

          2. severe co-morbid illness and/or active infections

          3. NCI CTCAE Grade 3 hemorrhage from any cause &lt; 4 weeks before enrollment

          4. preexisting uncontrolled hypertension as documented by 2 baseline blood pressure
             readings taken at least 1 hour apart

          5. pregnant or lactating women

          6. active CNS metastases not controllable with radiotherapy or corticosteroids

          7. active and uncontrollable bleeding from gastrointestinal tract

          8. known history of hypersensitivity to study drugs

          9. prior treatment with sunitinib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeeyun Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced gastric cancer</keyword>
  <keyword>sunitinib</keyword>
  <keyword>docetaxel</keyword>
  <keyword>fluoropyrimidine platinum based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

